Meeting NewsVideo

VIDEO: Recent trials impact first-line management of chronic lymphocytic leukemia

SAN DIEGO — In this video, Jeff Sharman, MD, medical director for hematology research at the U.S. Oncology Network and director of research at Willamette Valley Cancer Institute in Oregon, reviews top-line data on chronic lymphocytic leukemia that was presented at the ASH Annual Meeting and Exposition.

The research Sharman highlights includes an abstract from the plenary session that evaluated the addition of rituximab (Rituxan; Genentech, Biogen) to ibrutinib (Imbruvica; Pharmacyclics, Janssen) and compared ibrutinib with the standard-of-care chemotherapy/antibody regimen for CLL; a late-breaking abstract that evaluated the combination of ibrutinib and rituximab with standard chemoimmunotherapy among previously untreated younger patients with CLL; another late-breaking trial that characterized a mutation in the BCL2 protein conferring resistance to venetoclax (Venclexta; AbbVie, Genentech); and a study comparing venetoclax plus obinutuzumab (Gazyva, Genentech) vs. chlorambucil (Leukeran, Aspen Global) plus obinutuzumab.

“These are four, very important trials for the first-line management of CLL,” Sharman said.

References:

Blombery, et al. Abstract LBA-7. Presented at: ASH Annual Meeting and Exposition; Dec. 1-4, 2018; San Diego.

Shanafelt TD, et al. Abstract LBA-4. Presented at: ASH Annual Meeting and Exposition; Dec. 1-4, 2018; San Diego.

Woyach JA, et al. Abstract 6. Presented at: ASH Annual Meeting and Exposition; Dec. 1-4, 2018; San Diego.

Disclosure: Sharman reports receiving consulting fees and research funding from AbbVie, Acerta, Celgene, Genentech, Gilead, Pharmacyclics, Seattle Genetics and TG Therapeutics.

SAN DIEGO — In this video, Jeff Sharman, MD, medical director for hematology research at the U.S. Oncology Network and director of research at Willamette Valley Cancer Institute in Oregon, reviews top-line data on chronic lymphocytic leukemia that was presented at the ASH Annual Meeting and Exposition.

The research Sharman highlights includes an abstract from the plenary session that evaluated the addition of rituximab (Rituxan; Genentech, Biogen) to ibrutinib (Imbruvica; Pharmacyclics, Janssen) and compared ibrutinib with the standard-of-care chemotherapy/antibody regimen for CLL; a late-breaking abstract that evaluated the combination of ibrutinib and rituximab with standard chemoimmunotherapy among previously untreated younger patients with CLL; another late-breaking trial that characterized a mutation in the BCL2 protein conferring resistance to venetoclax (Venclexta; AbbVie, Genentech); and a study comparing venetoclax plus obinutuzumab (Gazyva, Genentech) vs. chlorambucil (Leukeran, Aspen Global) plus obinutuzumab.

“These are four, very important trials for the first-line management of CLL,” Sharman said.

References:

Blombery, et al. Abstract LBA-7. Presented at: ASH Annual Meeting and Exposition; Dec. 1-4, 2018; San Diego.

Shanafelt TD, et al. Abstract LBA-4. Presented at: ASH Annual Meeting and Exposition; Dec. 1-4, 2018; San Diego.

Woyach JA, et al. Abstract 6. Presented at: ASH Annual Meeting and Exposition; Dec. 1-4, 2018; San Diego.

Disclosure: Sharman reports receiving consulting fees and research funding from AbbVie, Acerta, Celgene, Genentech, Gilead, Pharmacyclics, Seattle Genetics and TG Therapeutics.

    See more from ASH Annual Meeting and Exposition